Seguir
Jonathan Pol
Jonathan Pol
INSERM, Centre de Recherche des Cordeliers (Paris), Gustave Roussy Cancer Campus (Villejuif)
Dirección de correo verificada de inserm.fr
Título
Citado por
Citado por
Año
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
8782014
Caloric restriction mimetics enhance anticancer immunosurveillance
F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ...
Cancer cell 30 (1), 147-160, 2016
5402016
First oncolytic virus approved for melanoma immunotherapy
J Pol, G Kroemer, L Galluzzi
Oncoimmunology 5 (1), e1115641, 2016
3772016
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
J Pol, E Vacchelli, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008866, 2015
3162015
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
P Liu, L Zhao, J Pol, S Levesque, A Petrazzuolo, C Pfirschke, C Engblom, ...
Nature communications 10 (1), 1486, 2019
2662019
The molecular hallmarks of the serrated pathway in colorectal cancer
FDE De Palma, V D’argenio, J Pol, G Kroemer, MC Maiuri, F Salvatore
Cancers 11 (7), 1017, 2019
2342019
Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies
S Gujar, JG Pol, Y Kim, PW Lee, G Kroemer
Trends in immunology 39 (3), 209-221, 2018
2032018
Maraba virus as a potent oncolytic vaccine vector
JG Pol, L Zhang, BW Bridle, KB Stephenson, J Rességuier, S Hanson, ...
Molecular therapy 22 (2), 420-429, 2014
2012014
Trial watch: peptide-based vaccines in anticancer therapy
L Bezu, O Kepp, G Cerrato, J Pol, J Fucikova, R Spisek, L Zitvogel, ...
Oncoimmunology 7 (12), e1511506, 2018
1752018
Effects of interleukin-2 in immunostimulation and immunosuppression
JG Pol, P Caudana, J Paillet, E Piaggio, G Kroemer
The Journal of Experimental Medicine 217 (1), 2020
1702020
Trial watch: Oncolytic viruses for cancer therapy
J Pol, N Bloy, F Obrist, A Eggermont, J Galon, I Cremer, P Erbs, ...
Oncoimmunology 3 (6), e28694, 2014
1582014
Trial Watch—Oncolytic viruses and cancer therapy
J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ...
Oncoimmunology 5 (2), e1117740, 2016
1442016
Trial Watch: Peptide-based anticancer vaccines
J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ...
Oncoimmunology 4 (4), e974411, 2015
1442015
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy
ST Workenhe, G Simmons, JG Pol, BD Lichty, WP Halford, KL Mossman
Molecular Therapy 22 (1), 123-131, 2014
1362014
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy
BW Bridle, L Chen, CG Lemay, JS Diallo, J Pol, A Nguyen, A Capretta, ...
Molecular Therapy 21 (4), 887-94, 2013
1322013
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
S Gujar, JG Pol, G Kroemer
OncoImmunology, e1442169, 2018
1302018
Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity
JM Bravo-San Pedro, V Sica, I Martins, J Pol, F Loos, MC Maiuri, ...
Cell Metabolism 30 (4), 754-767. e9, 2019
1082019
Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance
N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ...
Immunological reviews 280 (1), 165-174, 2017
1062017
Metabolic vulnerability of cisplatin‐resistant cancers
F Obrist, J Michels, S Durand, A Chery, J Pol, S Levesque, A Joseph, ...
The EMBO journal 37 (14), e98597, 2018
1052018
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
A Buqué, N Bloy, M Perez-Lanzón, K Iribarren, J Humeau, JG Pol, ...
Nature Communications 11 (1), 3819, 2020
982020
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20